The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial
Open accessAbstract
Background and Purpose—: The proinflammatory cytokine IL-1 (interleukin-1) has a deleterious role in cerebral ischemia, which is attenuated by IL-1 receptor antagonist (IL-1Ra). IL-1 induces peripheral inflammatory mediators, such as interleukin-6, which are associated with worse prognosis after ischemic stroke. We investigated whether subcutaneous IL-1Ra reduces the peripheral inflammatory response in acute ischemic stroke. Methods—: SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke) was a single-center, double-blind, randomized, placebo-controlled phase 2 trial of subcutaneous IL-1Ra (100 mg administered twice daily for 3 days) in patients presenting within 5 hours of ischemic stroke onset. Randomization was stratified for baseline National Institutes of Health Stroke Scale score and thrombolysis. Measurement of plasma interleukin-6 and other peripheral inflammatory markers was undertaken at 5 time points. The primary outcome was difference in concentration of log(interleukin-6) as area under the curve to day 3. Secondary outcomes included exploratory effect of IL-1Ra on 3-month outcome with the modified Rankin Scale. Results—: We recruited 80 patients (mean age, 72 years; median National Institutes of Health Stroke Scale, 12) of whom 73% received intravenous thrombolysis with alteplase. IL-1Ra significantly reduced plasma interleukin-6 ( P <0.001) and plasma C-reactive protein ( P <0.001). IL-1Ra was well tolerated with no safety concerns. Allocation to IL-1Ra was not associated with a favorable outcome on modified Rankin Scale: odds ratio (95% confidence interval)=0.67 (0.29–1.52), P =0.34. Exploratory mediation analysis suggested that IL-1Ra improved clinical outcome by reducing inflammation, but there was a statistically significant, alternative mechanism countering this benefit. Conclusions—: IL-1Ra reduced plasma inflammatory markers which are known to be associated with worse clinical outcome in ischemic stroke. Subcutaneous IL-1Ra is safe and well tolerated. Further experimental studies are required to investigate efficacy and possible interactions of IL-1Ra with thrombolysis. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: ISRCTN74236229
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DAMP Signaling is a Key Pathway Inducing Immune Modulation after Brain Injury
Liesz, A., Dalpke, A., Mracsko, E., Roth, S., Zhou, W., Yang, H., Na, S.-Y., Akhisaroglu, M., Fleming, T., Eigenbrod, T., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2439-14.2015 · Cited by 334
Maysami, S., Wong, R., Pradillo, J. M., Denes, A., Dhungana, H., Malm, T., Koistinaho, J., Orset, C., Rahman, M., Rubio, M., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15606714 · Cited by 84
Self-citation
Cited by
Neuroinflammation, Stroke, Blood-Brain Barrier Dysfunction, and Imaging Modalities
Candelario-Jalil, E., Dijkhuizen, R. M., & Magnus, T. (2022) · Stroke · doi:10.1161/strokeaha.122.036946 · Cited by 953
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions
Qin, C., Yang, S., Chu, Y.-H., Zhang, H., Pang, X.-W., Chen, L., Zhou, L.-Q., Chen, M., Tian, D.-S., & Wang, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01064-1 · Cited by 939
Immune responses to stroke: mechanisms, modulation, and therapeutic potential.
Iadecola, C., Buckwalter, M. S., & Anrather, J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135530 · Cited by 853
Jurcau, A., & Simion, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010014 · Cited by 500
Post-stroke inflammation—target or tool for therapy?
Lambertsen, K. L., Finsen, B., & Clausen, B. H. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1930-z · Cited by 465
Metadata
- Authors
- Smith, C. J., Hulme, S., Vail, A., Heal, C., Parry-Jones, A. R., Scarth, S., Hopkins, K., Hoadley, M., Allan, S. M., Rothwell, N. J., Hopkins, S. J., & Tyrrell, P. J.
- Venue
- Stroke
- Published
- 2018-05
- Volume
- 49
- Issue
- 5
- Pages
- 1210-1216
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2792355005
- Cited by
- 197
- References
- 2
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial. https://app.cochat.ai/papers/10.1161/strokeaha.118.020750
- The paper
- Smith, C. J., Hulme, S., Vail, A., Heal, C., Parry-Jones, A. R., Scarth, S., Hopkins, K., Hoadley, M., Allan, S. M., Rothwell, N. J., Hopkins, S. J., & Tyrrell, P. J. (2018). SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial. Stroke. https://doi.org/10.1161/strokeaha.118.020750
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.